InvestorsHub Logo
Followers 2563
Posts 59174
Boards Moderated 2
Alias Born 06/04/2004

Re: None

Wednesday, 03/29/2017 7:08:57 PM

Wednesday, March 29, 2017 7:08:57 PM

Post# of 1317
HEALTH ADVANCE INC patent-pending product formulations for cebidiofen and polyoxfen gained a special interest among 81% of the pain medicine physicians that participated in the market research study, opposed to the 19% who thought that there were not better alternatives for opium derivatives like oxycodone, hydrocodone, buprenorphine, oxymorphone, and hydromorphone.